Target intelligence / Profile preview

Solute carrier family 22 member 4 (SLC22A4 (OCTN1))

Target
SLC22A4 (OCTN1)
Molecular classification
Transporter, Solute carrier family (SLC), Organic cation transporter protein
01

Overview

Solute carrier family 22 member 4 (SLC22A4), also known as organic cation transporter novel type 1 (OCTN1), encodes an integral membrane protein containing 12 transmembrane domains and functions as a Na⁺-dependent, high-affinity transporter for ergothioneine, an antioxidant amino acid. It also accepts a range of organic cations and zwitterions as substrates, showing low transport efficiency for carnitine and certain other molecules. OCTN1 is expressed in numerous tissues including liver, intestine, kidney, heart, brain, and placenta, implied to be important for antioxidant supply and cellular defense against oxidative stress. Genetic variants of SLC22A4 have been associated with susceptibility to inflammatory and autoimmune conditions. Correction Note: SLC22A4/OCTN1 is not a sodium/hydrogen exchanger. The sodium/hydrogen exchanger isoform 3 is encoded by a different gene, SLC9A3. Instead, SLC22A4 is primarily an ergothioneine and organic cation transporter.

Other names
Organic cation transporter 1 (OCTN1)Ergothioneine transporter (ETT)SLC22A4
02

Mechanism of action

Competitive inhibition (some drugs compete for transport) Substrate translocation across the plasma membrane

03

Biological functions

Ergothioneine uptake (antioxidant transport)Organic cation and zwitterion transportCell protection against oxidative stress
04

Disease associations

Inflammation (polymorphisms linked to Crohn’s disease and other autoimmune disorders)Other (potential roles in neurodegenerative diseases, cardiovascular diseases, based on oxidative stress mediation)
05

Safety considerations

Limited drug selectivity leading to potential off-target effectsPolyspecificity may affect pharmacokinetics and drug safety profile (unintended substrate interaction)
06

Interacting drugs

Desipramine

5 more in the full profile.

07

Biomarkers

Polymorphisms in SLC22A4 (in Crohn’s disease and autoimmune risk stratification)

Beyond the preview

Go deeper on Solute carrier family 22 member 4 (SLC22A4 (OCTN1)).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Solute carrier family 22 member 4 (SLC22A4 (OCTN1)).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call